eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2020
vol. 6
 
Share:
Share:
abstract:
Original paper

Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled, double-blinded study

Hossam Z Mohamed
1
,
Nagwa A Sabri
2
,
Hossam M Zaki
1
,
Sara M Shaheen
2

1.
Hepatology Department, Kobri El koba Armed Forces Hospital, Cairo, Egypt
2.
Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
Clin Exp HEPATOL 2020; 6, 2: 99–105
Online publish date: 2020/05/25
View full text Get citation
 
PlumX metrics:
Aim of the study
Chronic hepatitis C (CHC) affects more than 71 million people worldwide. Many therapies containing different direct-acting antivirals (DAAs) are now used. However, lipid profile is considered an important outcome with DAAs. So, this study aimed to assess clinical effects of statins in CHC patients.

Material and methods
One hundred patients were recruited from Kobri El koba Armed Forces Hospital and randomly assigned to: the drug group (D; n = 50) receiving simvastatin 10 mg plus sofosbuvir 400 mg/daclatasvir 60 mg (SOF/DAC) daily for 12 weeks; and the placebo group (P; n = 50), receiving placebo plus the same (SOF/DAC) regimen. Sustained virological response at 12 weeks after treatment (SVR12), lipid profile, C-reactive protein (CRP) and fibrosis stage were assessed.

Results
One hundred treatment-naïve CHC patients completed 12 weeks of the protocol with no clinically significant side effects. There was an increase in SVR failure rate in P (10%) compared to D (only 2%) but not reaching statistical significant difference; SVR12 (p > 0.05). Logistic regression analysis showed that high baseline CRP, low baseline hemoglobin level and non-statin usage had an independent effect on increasing the probability of SVR failure in both groups; p = 0.03, p = 0.0028, p = 0.02, respectively.

Conclusions
Statins could have an irreplaceable role in successful treatment of CHC patients receiving sofosbuvir/daclatasvir.

keywords:

chronic hepatitis C, statins, sofosbuvir/daclatasvir

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.